Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Wenxin Xu, M.D.


Harvard Medical School, Boston, MAMD2014Medicine
Beth Israel Deaconess Medical Center, Boston, MA2017Internal Medicine
Beth Israel Deaconess Medical Center, Boston, MA2020Hematology/Oncology

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. W81XWH-22-1-0951 (Wenxin Xu) Oct 1, 2022 - Sep 30, 2026
    Department of Defense, CDMRP Kidney Cancer Research Program
    Circulating Biomarkers in Renal Cell Carcinoma
    Role: Principal Investigator
  2. Young Investigator Award (Wenxin Xu) Jul 1, 2020 - Jun 30, 2021
    ASCO Conquer Cancer Foundation
    Kidney Injury Molecule-1 in renal cell carcinoma
    Role: Principal Investigator
  3. Career Enhancement Award (Wenxin Xu) Sep 1, 2019 - Aug 31, 2020
    DF/HCC Kidney Cancer SPORE
    Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a biomarker in renal cell carcinoma
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, El Zarif T, Saliby RM, Wan G, Rajeh A, Adib E, Nuzzo PV, Schmidt AL, Labaki C, Ricciuti B, Alessi JV, Braun DA, Shukla SA, Keenan TE, Van Allen E, Awad MM, Manos M, Rahma O, Zubiri L, Villani AC, Fairfax B, Hammer C, Khan Z, Reynolds K, Semenov Y, Schrag D, Kehl KL, Freedman ML, Choueiri TK, Gusev A. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022 12; 28(12):2584-2591. PMID: 36526723.
    Citations:    Fields:    Translation:Cells
  2. Nassar AH, Adib E, Abou Alaiwi S, El Zarif T, Groha S, Akl EW, Nuzzo PV, Mouhieddine TH, Perea-Chamblee T, Taraszka K, El-Khoury H, Labban M, Fong C, Arora KS, Labaki C, Xu W, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Zaitlen N, Schoenfeld AJ, Schultz N, Berger MF, MacConaill LE, Ananda G, Kwiatkowski DJ, Choueiri TK, Schrag D, Carrot-Zhang J, Gusev A. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. Cancer Cell. 2022 10 10; 40(10):1161-1172.e5. PMID: 36179682; PMCID: PMC9559771.
    Citations: 1     Fields:    Translation:Humans
  3. Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022 Jul; 175:103706. PMID: 35537621.
    Citations:    Fields:    Translation:Humans
  4. Kehl KL, Xu W, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, Schrag D. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nat Commun. 2021 12 15; 12(1):7304. PMID: 34911934; PMCID: PMC8674229.
    Citations:    Fields:    Translation:Humans
  5. Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 01; 7(12):1815-1823. PMID: 34673916; PMCID: PMC8532040.
    Citations: 7     Fields:    Translation:Humans
  6. Schmidt AL, Tucker MD, Bakouny Z, Labaki C, Hsu CY, Shyr Y, Armstrong AJ, Beer TM, Bijjula RR, Bilen MA, Connell CF, Dawsey SJ, Faller B, Gao X, Gartrell BA, Gill D, Gulati S, Halabi S, Hwang C, Joshi M, Khaki AR, Menon H, Morris MJ, Puc M, Russell KB, Shah NJ, Sharifi N, Shaya J, Schweizer MT, Steinharter J, Wulff-Burchfield EM, Xu W, Zhu J, Mishra S, Grivas P, Rini BI, Warner JL, Zhang T, Choueiri TK, Gupta S, McKay RR. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. JAMA Netw Open. 2021 11 01; 4(11):e2134330. PMID: 34767021; PMCID: PMC8590166.
    Citations: 9     Fields:    Translation:Humans
  7. Yekedüz E, Trapani D, Xu W, de Vries EGE, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. Int J Cancer. 2021 10 01; 149(7):1455-1462. PMID: 34124786.
    Citations:    Fields:    Translation:Humans
  8. Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clin Cancer Res. 2021 06 15; 27(12):3397-3403. PMID: 33832947; PMCID: PMC8287837.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  9. Braun DA, Street K, Burke KP, Cookmeyer DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L, Hirsch L, Bakouny Z, Hou Y, Forman J, Huang T, Li S, Cui A, Keskin DB, Steinharter J, Bouchard G, Sun M, Pimenta EM, Xu W, Mahoney KM, McGregor BA, Hirsch MS, Chang SL, Livak KJ, McDermott DF, Shukla SA, Olsen LR, Signoretti S, Sharpe AH, Irizarry RA, Choueiri TK, Wu CJ. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8. PMID: 33711273.
    Citations: 38     Fields:    Translation:HumansCells
  10. Xu W, Piper-Vallillo AJ, Bindal P, Wischhusen J, Patel JM, Costa DB, Peters MLB. Time to SARS-CoV-2 clearance among patients with cancer and COVID-19. Cancer Med. 2021 03; 10(5):1545-1549. PMID: 33560590.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  11. Kehl KL, Xu W, Lepisto E, Elmarakeby H, Hassett MJ, Van Allen EM, Johnson BE, Schrag D. Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes. JCO Clin Cancer Inform. 2020 08; 4:680-690. PMID: 32755459.
    Citations: 7     Fields:    Translation:Humans
  12. Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020 03; 17(3):137-150. PMID: 32020040.
    Citations: 57     Fields:    Translation:Humans
  13. Varkaris A, Xu W, Davis RB, Healy B, McDermott DF. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020 06; 18(3):179-184.e3. PMID: 32144046; PMCID: PMC7875559.
    Citations: 2     Fields:    Translation:Humans
  14. Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clin Cancer Res. 2019 10 15; 25(20):6098-6106. PMID: 31471309.
    Citations: 8     Fields:    Translation:Humans
  15. Xu W, Bubley GJ. Repurposed Drugs for Prostate Cancer. Cancer J. 2019 Mar/Apr; 25(2):121-126. PMID: 30896534.
    Citations: 1     Fields:    Translation:Humans
  16. Xu W, Shubina M, Goldberg SI, Turchin A. Body mass index and all-cause mortality in patients with hypertension. Obesity (Silver Spring). 2015 Aug; 23(8):1712-20. PMID: 26179058.
    Citations: 7     Fields:    Translation:Humans
  17. Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015 Feb 05; 350:h158. PMID: 25655523; PMCID: PMC4353282.
    Citations: 46     Fields:    Translation:Humans
  18. Brown KM, Costanzo MS, Xu W, Roy S, Lozovsky ER, Hartl DL. Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. Mol Biol Evol. 2010 Dec; 27(12):2682-90. PMID: 20576759.
    Citations: 43     Fields:    Translation:Animals
  19. Stevens JB, Liu G, Bremer SW, Ye KJ, Xu W, Xu J, Sun Y, Wu GS, Savasan S, Krawetz SA, Ye CJ, Heng HH. Mitotic cell death by chromosome fragmentation. Cancer Res. 2007 Aug 15; 67(16):7686-94. PMID: 17699772.
    Citations: 28     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Xu's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (92)
Co-Authors (60)
Similar People (59)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.